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Introduction
In 1963, Randle et al. (1) postulated a glucose/fatty acid cycle in which FFA compete with glucose as a physiological sub-An additional effect of FFA, its increase of hepatic glucose output, was postulated shortly after Randle's original proposal (6) (7) (8) (9) . Most in vitro studies have found that FFA augment gluconeogenesis (6) (7) (8) (9) (10) (11) (12) (13) . However, in vivo studies have yielded conflicting results concerning the effects of FFA on overall hepatic glucose output (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . Thus, the effect of FFA on hepatic glucose output and gluconeogenesis in vivo remain in doubt.
During counterregulation of hypoglycemia, plasma FFA concentrations and rates of lipid oxidation increase (23, 26) . This is temporally associated with an increase in glucose production and a suppression of glucose utilization (23, 26) . Therefore, it has been postulated recently that FFA may mediate some of the changes in glucose metabolism that occur during counterregulation of hypoglycemia (23) .
To test this hypothesis and to determine the relative impact of alterations in FFA availability on glucose production and glucose utilization, we assessed the effect ofacipimox, an inhibitor of lipolysis (19, 24) , on glucose production, gluconeogenesis, and glucose utilization, as well as plasma alanine fluxes during counterregulation of insulin-induced hypoglycemia in normal volunteers.
Methods
Subjects. Informed consent was obtained from eight healthy volunteers (four males and four females) aged 25±1 yr who were all within 10% of their ideal body weight ( 101±2%, Metropolitan Life Insurance Tables; body mass index of 24.4±1.0 kg/im2) and had no family history of diabetes mellitus or other endocrine disease. Each subject was studied on two different occasions: control experiments without acipimox were performed first, followed by experiments with acipimox 7-10 d later. For 3 d before each experiment, all subjects consumed a weight maintenance diet containing 2 250 g carbohydrate.
Protocol. Institutional Review Board approval was obtained for these studies. In both experiments, subjects were admitted to the Clinical Research Center between 6:30 and 7:00 a.m., after overnight fasting ( 10-12 h (28 uCi, 0.28 gCi/min) (Amersham Corp., Arlington Heights, IL) were begun. 3 h were allowed for isotopic equilibration, after which baseline blood samples were taken. Lipid and carbohydrate oxidation expenditure were measured in all subjects by indirect calorimetry (28) . 90 min before beginning experiments, a transparent plastic ventilated hood was placed over the subject's head and made airtight around the neck. Air flow and 02 and CO2 concentrations in the expired and inspired air were measured by a computerized continuous open-circuit system (Deltatrac; Datex Instruments Co., Helsinki, Finland) (29) that has a precision of 2.5% for oxygen consumption and 1.0% for carbon dioxide production. Protein oxidation was estimated from urinary excretion ofurea before and during insulin hypoglycemia. After the subjects had adapted to the hood and stabilized their breathing pattern, gas-exchange measurements were taken during a 45-min basal period and were continued throughout the studies.
In control experiments, insulin (regular U-40; Eli Lilly & Co., Indianapolis, IN), diluted to 1 U/ml in 100 ml of0.9% NaCl containing 2 ml of the subject's blood, was infused at the rate of 0.35 mU * Kg-' -min-' for 8 h to induce moderate hypoglycemia. In acipimox experiments, insulin was infused as in the control experiments and acipimox (5-methyl-pyrazene-carboxylic acid 4-oxide) (Olbetam, Farmitalia Carlo Erba, Milan, Italy) (250 mg p.o.) was given 60 min after starting the insulin infusion and again at 240 min to inhibit lipolysis. Because we anticipated from previous studies (23) that suppression of lipolysis might impair glucose counterregulation, glucose was infused when needed to maintain plasma glucose concentrations identical to those in the control experiments using the glucose-clamp technique as previously described (23) .
Analyses. Blood samples were collected at 30-min intervals and assayed for glucose (Beckman glucose analyzer; Beckman Instruments, Fullerton, CA), alanine (30) (30) , and glycerol (30) . For FFA determination, blood (2 ml) was collected in tubes containing 50i1 of the lipoproteinlipase inhibitor diethyl-p-nitrophenyl-phosphate (Paraoxon; Sigma Chemical Co., St. Louis, MO) diluted to 0.04% in diethyl ether (32) . Urine was collected from the onset to the end of each study period to determine nitrogen excretion using the Kjeldahl method (33) .
Calculations. Oxidation rates for carbohydrate, fat, and protein were calculated from the measured 02 consumption, CO2 production, and urinary nitrogen excretion before and during the insulin infusion adjusted for changes in serum urea during insulin infusion (34, 35) . Rates ofglucose and alanine appearance (Ra) and disappearance (Rd) were calculated using the non-steady-state equations of De Bodo et al. (36) ; a pool size of 0.65 and a distribution of 200 mg/kg were used. When glucose was infused, endogenous glucose appearance was calculated by subtracting the exogenous glucose infusion rate from the overall glucose appearance. Gluconeogenesis was estimated as the rate of appearance of glucose from alanine calculated using the non-steadystate double isotope technique of Chiasson et al. (37) in which the appearance of 14C in glucose is traced by [3 
H] glucose. Data in text and
figures are given as mean±SEM, and the statistical significance was evaluated using Student's paired t test. A P < 0.05 was considered significant.
Results
Plasma insulin and glucose concentrations, and glucose infusion rates (Fig. 1 ). Baseline and subsequent plasma insulin concentrations were comparable in the control and acipimox experiments. During infusion of insulin, plasma glucose levels decreased similarly in both experiments to a plateau of -3.0 mM. However, in the acipimox experiments, glucose had to be infused to maintain the plasma glucose concentrations compa- (Figs. 4 and 5) . Baseline hepatic glucose output was comparable in both experiments. In control experiments, it decreased transiently after starting the insulin infusion and then increased to a peak rate of 12.1 ± 1.1 mol/kg per min at 210 min. In the acipimox experiments, hepatic glucose output was similar to that in control experiments through 240 min but afterwards was consistently less. Thus during the last 240 min hepatic glucose output was only 5.5±1.1 ,umol/kg per min in acipimox experiments compared to 9.3±0.7,gmol/kg per min in control experiments, P < 0.01.
Baseline rates ofgluconeogenesis from alanine were comparable in both experiments. In control experiments, it increased progressively after 240 min, reaching values more than threefold above baseline. In the acipimox experiments, gluconeogenesis did not increase at all, and during the last 240 min, averaged only 0.32±0.09 ,mol/kg per min compared to 1.00±0.18
,umol/kg per min in control experiments, P < 0.001. As shown in Fig. 5 , rates of gluconeogenesis during the last 240 min of both experiments were positively correlated with rates of lipid oxidation (r = 0.91, P < 0.001).
Plasma alanine concentration, appearance, and disappearance (Fig. 6) . Baseline plasma alanine concentrations were comparable in both experiments. In the control experiments during infusion of insulin, plasma alanine gradually decreased by -130,gmol/liter over the course of the study. In the acipimox experiments, plasma alanine decreased significantly less (by 90 ,gmol/liter), so that at the end of the study it averaged 250±36 vs. 190±22 MM in control experiments, P < 0.01.
Baseline rates ofplasma alanine appearance and disappearance were comparable in both experiments. In control experi- ments, after a transient decrease after starting the insulin infusion, plasma alanine appearance returned to basal rates after 120 min. In the acipimox experiments, plasma alanine appearance remained suppressed throughout so that during the last hour of the experiment, it averaged 5.0±1.2 vs. 6.8± 1.1 ymol/ kg per min in control experiments, P < 0.05. In control experiments, the proportion of alanine appearing in plasma that was converted to plasma glucose increased from 13±3% at baseline to 32±2% by the end ofthe experiment (P < 0.001), whereas in the acipimox experiments, it did not increase (12±3% at baseline vs. 10±2% at the end of the experiment).
Rates of plasma alanine disappearance in control experiments transiently decreased after start of the insulin infusion and then rose to slightly above basal values (7.8± 1.1 mol/kg per min at 480 min vs. 6.7±1.3 gmol/kg per min at baseline, P < 0.05). In contrast in the acipimox experiments, after a transient decrease and return to rates comparable to those in control experiments, plasma alanine disappearance progressively decreased, so that at the end ofthe experiment, it averaged only 4.7± 1.2 ymol/kg per min, P < 0.01 vs. the control experiment.
Glucose utilization and oxidation (Figs. 4 and 7) . Rates of glucose utilization and oxidation were comparable in both experiments at baseline and for the initial 150-180 min. Subsequently both glucose utilization and glucose oxidation were consistently greater in the acipimox experiments. During the last 240 min of the study, glucose utilization and oxidation averaged 10.8± 1.4 and 9.5± 1.3 Mmol/kg per min, respectively, vs. 9.3±0.7 and 4.8±1.0 Amol/kg per min in control experiments, both P < 0.01. As shown in Fig. 7 , rates of glucose utilization and oxidation during the last 240 min ofboth exper- best of our knowledge, these results provide the first clear cut evidence for a dependency ofan increase ingluconeogenesis on an increase in FFA availability in vivo. It has been proposed that most of the compensatory increase in hepatic glucose output during prolonged counterregulation is due to gluconeogenesis (38, 39) . Our results support this view. Alanine usually accounts for -15% ofoverall gluconeogenesis (40) . The reduction in conversion of alanine to glucose (0.7 Amol/kg per min glucose equivalents) observed in the present study during inhibition of lipolysis suggests that suppression of gluconeogenesis accounted for substantially all of the associated reduction in hepatic glucose output (3.8 ,gmol/kg per min).
As expected (1 1) (see below), the mechanism for the suppression of gluconeogenesis during inhibition of lipolysis by acipimox appeared to be intrahepatic since the fractional conversion of alanine to glucose by the liver was reduced despite the fact that alanine availability, as reflected by plasma alanine concentrations, was increased. This increase in plasma alanine occurred because its rate of disappearance from plasma decreased more than its rate of appearance decreased. The latter might reflect the fact that more glucose was being oxidized during the inhibition of lipolysis, and, therefore, less glucose was available for conversion to alanine. The decrease in alanine disappearance from plasma might simply reflect less alanine being used for gluconeogenesis.
Presumably the effects ofacipimox on gluconeogenesis and glucose utilization were mediated by suppression of lipid oxidation secondary to inhibition oflipolysis. This is supported by the correlations that we found between rates of lipid oxidation and rates of both gluconeogenesis (r = 0.91 ) and glucose utilization (r = -0.71 ) and by the temporal relationship between changes in lipid oxidation and those of gluconeogenesis and glucose utilization. Inhibition of lipid oxidation within the liver could suppress gluconeogenesis by several mechanisms ( 1): (a) limitation of NADH needed for the glyceraldehyde 3-phosphate dehydrogenase reaction; (b) reduction of ATP needed to support gluconeogenesis; and (c) suppression ofacetyl-coenzyme A and other thio-esters needed to activate pyruvate carboxylase. Some other action of acipimox on hepatic glucose output not involving FFA oxidation appears unlikely since Saloranta et al. ( 19) were able to completely reverse the effects of acipimox on hepatic glucose production by restoration of FFA availability. Moreover, nicotinic acid, of which acipimox is a derivative, has no direct effect on gluconeogenesis by the perfused rat liver ( 13 ) . Regarding glucose utilization, inhibition of lipid oxidation could increase glucose uptake and oxidation by a complex set of mechanisms recently reviewed by Randle et al. (2) . The observation by Piatti et al. (5) that acipimox did not further increase forearm glucose uptake when plasma FFA were already markedly suppressed by insulin argues against an effect of acipimox on glucose utilization not involving changes in FFA availability.
Although most in vitro studies have found that FFA increase gluconeogenesis (6-13), a consistent effect on overall hepatic glucose output in vivo has not been demonstrated (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . In addition to the present experiments, only one other study (22) has directly examined the effect ofFFA on gluconeogenesis and overall hepatic glucose output in humans. In that study, Clore et al. (22) found that increasing FFA availability increased gluconeogenesis from alanine consistent with our 1620 Fanelli et al. finding that a reduction in FFA availability reduced gluconeogenesis from alanine. However, Clore et al. (22) found no change in overall hepatic glucose output whereas in our study overall hepatic glucose output was markedly reduced.
An explanation for this difference may relate to two factors. First of all, there appears to be some autoregulatory mechanism, probably involving inhibition of glycogenolysis, by which an increase in gluconeogenesis does not necessarily increase overall hepatic glucose output (41, 42) . This may explain why Clore et al. (22) observed no increase in overall hepatic glucose output. Secondly, suppression ofgluconeogenesis in our experiments probably decreased overall hepatic glucose output because under our experimental conditions gluconeogenesis was responsible for most of hepatic glucose output (38, 39) . Moreover, a compensatory increase in glycogenolysis would have been minimal because of the ongoing insulin infusion and because ofprevious glycogen depletion caused by glycogenolysis earlier during counterregulation and nearly 24 h of fasting. Support for this explanation is provided by studies (42, 43) in which inhibition ofgluconeogenesis by ethanol in overnight fasted volunteers who would have had glycogen reserves did not affect hepatic glucose output, whereas it did reduce hepatic glucose output in 69-h-fasted volunteers whose glycogen would have been depleted (44) .
In summary, the present studies demonstrate that inhibition of lipolysis by acipimox during counterregulation of insulin-induced hypoglycemia reduced overall hepatic glucose output by 40% and gluconeogenesis from alanine by 70% while increasing glucose utilization by 15%. These results indicate that FFA play a role in mediating changes in glucose metabolism that occur during counterregulation and that, under these conditions, FFA exert a much more profound effect on hepatic glucose production than on glucose utilization. Finally, our results suggest that increased FFA availability/oxidation may be a prerequisite for increased gluconeogenesis.
